Kumait Al Lawati1,2,3, Sameer Sharif4,5, Said Al Maqbali1,3, Hussein Al Rimawi1, Andrew Petrosoniak6, Emilie P Belley-Cote2,7, Sunjay V Sharma2,8, Justin Morgenstern9, Shannon M Fernando10,11, Julian J Owen1,2, Michelle Zeller12, David Quinlan1, Waleed Alhazzani2,13, Bram Rochwerg2,13. 1. Division of Emergency Medicine, Department of Medicine, McMaster University, Hamilton, ON, Canada. 2. Division of Critical Care, Department of Medicine, McMaster University, Hamilton, ON, Canada. 3. Oman Medical Specialty Board (OMSB), Muscat, Sultanate of Oman. 4. Division of Emergency Medicine, Department of Medicine, McMaster University, Hamilton, ON, Canada. sameer.sharif@medportal.ca. 5. Division of Critical Care, Department of Medicine, McMaster University, Hamilton, ON, Canada. sameer.sharif@medportal.ca. 6. Division of Emergency Medicine, Department of Medicine, University of Toronto, Toronto, ON, Canada. 7. Population Health Research Institute, Hamilton, ON, Canada. 8. Division of Neurosurgery, Department of Surgery, McMaster University, Hamilton, ON, Canada. 9. Division of Emergency Medicine, Department of Family and Community Medicine, University of Toronto, Toronto, ON, Canada. 10. Department of Emergency Medicine, University of Ottawa, Ottawa, ON, Canada. 11. Division of Critical Care, Department of Medicine, University of Ottawa, Ottawa, ON, Canada. 12. McMaster Centre for Transfusion Research, McMaster University and Canadian Blood Services, Hamilton, Canada. 13. Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, ON, Canada.
Abstract
PURPOSE: With the publication of a large randomized-controlled trial (RCT) suggesting that tranexamic acid (TXA) may improve head-injury-related deaths, we aimed to determine the safety and efficacy of TXA in acute traumatic brain injury (TBI). METHODS: In this systematic review and meta-analysis, we searched MEDLINE, PubMed, EMBASE, CINHAL, ACPJC, Google Scholar, and unpublished sources from inception until June 24, 2020 for randomized-controlled trials comparing TXA and placebo in adults and adolescents (≥ 15 years of age) with acute TBI. We screened studies and extracted summary estimates independently and in duplicate. We assessed the quality of evidence using the grading of recommendations assessment, development, and evaluation approach. This study is registered with PROSPERO (CRD42020164232). RESULTS: Nine RCTs enrolled 14,747 patients. Compared to placebo, TXA had no effect on mortality (RR 0.95; 95% CI 0.88-1.02; RD 1.0% reduction; 95% CI 2.5% reduction to 0.4% increase, moderate certainty) or disability assessed by the Disability Rating Scale (MD, - 0.18 points; 95% CI - 0.43 to 0.08; moderate certainty). TXA may reduce hematoma expansion on subsequent imaging (RR 0.77; 95% CI 0.58-1.03, RD 3.6%, 95% CI 6.6% reduction to 0.5% increase, low certainty). Risks of adverse events (all moderate, low, or very low certainty) were similar between placebo and TXA. CONCLUSIONS: In patients with acute TBI, TXA probably has no effect on mortality or disability. TXA may decrease hematoma expansion on subsequent imaging; however, this outcome is likely of less importance to patients. The use of TXA probably does not increase the risk of adverse events.
PURPOSE: With the publication of a large randomized-controlled trial (RCT) suggesting that tranexamic acid (TXA) may improve head-injury-related deaths, we aimed to determine the safety and efficacy of TXA in acute traumatic brain injury (TBI). METHODS: In this systematic review and meta-analysis, we searched MEDLINE, PubMed, EMBASE, CINHAL, ACPJC, Google Scholar, and unpublished sources from inception until June 24, 2020 for randomized-controlled trials comparing TXA and placebo in adults and adolescents (≥ 15 years of age) with acute TBI. We screened studies and extracted summary estimates independently and in duplicate. We assessed the quality of evidence using the grading of recommendations assessment, development, and evaluation approach. This study is registered with PROSPERO (CRD42020164232). RESULTS: Nine RCTs enrolled 14,747 patients. Compared to placebo, TXA had no effect on mortality (RR 0.95; 95% CI 0.88-1.02; RD 1.0% reduction; 95% CI 2.5% reduction to 0.4% increase, moderate certainty) or disability assessed by the Disability Rating Scale (MD, - 0.18 points; 95% CI - 0.43 to 0.08; moderate certainty). TXA may reduce hematoma expansion on subsequent imaging (RR 0.77; 95% CI 0.58-1.03, RD 3.6%, 95% CI 6.6% reduction to 0.5% increase, low certainty). Risks of adverse events (all moderate, low, or very low certainty) were similar between placebo and TXA. CONCLUSIONS: In patients with acute TBI, TXA probably has no effect on mortality or disability. TXA may decrease hematoma expansion on subsequent imaging; however, this outcome is likely of less importance to patients. The use of TXA probably does not increase the risk of adverse events.
Authors: Geert Meyfroidt; Pierre Bouzat; Michael P Casaer; Randall Chesnut; Sophie Rym Hamada; Raimund Helbok; Peter Hutchinson; Andrew I R Maas; Geoffrey Manley; David K Menon; Virginia F J Newcombe; Mauro Oddo; Chiara Robba; Lori Shutter; Martin Smith; Ewout W Steyerberg; Nino Stocchetti; Fabio Silvio Taccone; Lindsay Wilson; Elisa R Zanier; Giuseppe Citerio Journal: Intensive Care Med Date: 2022-05-20 Impact factor: 41.787
Authors: Seif Tarek El-Swaify; Mazen A Refaat; Sara H Ali; Abdelrahman E Mostafa Abdelrazek; Pavly Wagih Beshay; Menna Kamel; Bassem Bahaa; Abdelrahman Amir; Ahmed Kamel Basha Journal: Trauma Surg Acute Care Open Date: 2022-01-05
Authors: Alexander P J Vlaar; Joanna C Dionne; Sanne de Bruin; Marije Wijnberge; S Jorinde Raasveld; Frank E H P van Baarle; Massimo Antonelli; Cecile Aubron; Jacques Duranteau; Nicole P Juffermans; Jens Meier; Gavin J Murphy; Riccardo Abbasciano; Marcella C A Müller; Marcus Lance; Nathan D Nielsen; Herbert Schöchl; Beverley J Hunt; Maurizio Cecconi; Simon Oczkowski Journal: Intensive Care Med Date: 2021-10-22 Impact factor: 17.440